GE Healthcare Life Sciences to build KUBio modular biopharmaceutical factory for JHL Biotech in China

GE Healthcare Life Sciences a business unit of GE Healthcare, and JHL Biotech, a provider of biopharmaceutical process development and manufacturing services, have announced that a KUBio™ modular biopharmaceutical factory will be built in China for JHL Biotech. The site for the new factory, which will be fully operational beginning early 2015, is the Biolake Science Park in Wuhan, China.
 
KUBio is a new approach to readily establish biopharmaceutical manufacturing capacity by delivering customers a fully functional, ready-to-run bioprocessing facility in 14-18 months, which is significantly shorter than constructing a traditional facility. Pre-designed to meet cGMP requirements, KUBio helps manufacturers, such as JHL Biotech, respond to local healthcare needs and support global customers in bringing life-saving treatments to market more quickly.
 
GE Healthcare’s innovative turnkey approach will involve the assembly at the JHL Biotech site in Wuhan, China of pre-made modules equipped with GE Healthcare’s world-class technologies for the start-to-finish manufacture of biopharmaceuticals. In addition to GE project-managing the build, members of its experienced Shanghai Fast Trak team will be deployed to validate the equipment and provide training for JHL Biotech staff.  After completion, the JHL Biotech KUBio facility will have a floor space of approximately 2,400m² and will contain a number of 2,000L single-use bioreactors.